Close Menu

artificial intelligence

In a PrecisionFDA challenge, DeepVariant calls of PacBio HiFi reads topped 99 percent precision and recall for SNVs and indels, bringing HiFi in line with Illumina. 

With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.

BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.

The firms will combine real-life data sets in rare diseases with expertise in big data, artificial intelligence, and computational algorithms.

The acquisition will give Curi access to Dana's portfolio of artificial intelligence and machine learning technologies for in vitro cell-based assays.

BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.  

The partners will use ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.

Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.

The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.

The firms plan to collaborate with others in the field of regenerative medicine and cell therapy to expedite commercialization of the system.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.